- Home
- LEGT vs ABEO Comparison
LEGT vs ABEO Comparison
Compare LEGT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGT
- ABEO
- Stock Information
- Founded
- LEGT 2023
- ABEO N/A
- Country
- LEGT United States
- ABEO United States
- Employees
- LEGT N/A
- ABEO N/A
- Industry
- LEGT
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- LEGT
- ABEO Health Care
- Exchange
- LEGT Nasdaq
- ABEO Nasdaq
- Market Cap
- LEGT 265.3M
- ABEO 277.6M
- IPO Year
- LEGT 2024
- ABEO 1980
- Fundamental
- Price
- LEGT $10.29
- ABEO $5.79
- Analyst Decision
- LEGT
- ABEO Strong Buy
- Analyst Count
- LEGT 0
- ABEO 3
- Target Price
- LEGT N/A
- ABEO $18.00
- AVG Volume (30 Days)
- LEGT 37.0K
- ABEO 332.6K
- Earning Date
- LEGT 01-01-0001
- ABEO 11-14-2024
- Dividend Yield
- LEGT N/A
- ABEO N/A
- EPS Growth
- LEGT N/A
- ABEO N/A
- EPS
- LEGT N/A
- ABEO N/A
- Revenue
- LEGT N/A
- ABEO N/A
- Revenue This Year
- LEGT N/A
- ABEO N/A
- Revenue Next Year
- LEGT N/A
- ABEO $7,097.06
- P/E Ratio
- LEGT N/A
- ABEO N/A
- Revenue Growth
- LEGT N/A
- ABEO 147.52
- 52 Week Low
- LEGT $10.00
- ABEO $3.05
- 52 Week High
- LEGT $10.47
- ABEO $9.01
- Technical
- Relative Strength Index (RSI)
- LEGT N/A
- ABEO 37.97
- Support Level
- LEGT N/A
- ABEO $5.63
- Resistance Level
- LEGT N/A
- ABEO $6.01
- Average True Range (ATR)
- LEGT 0.00
- ABEO 0.31
- MACD
- LEGT 0.00
- ABEO -0.07
- Stochastic Oscillator
- LEGT 0.00
- ABEO 14.66
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.